17,261 trials
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Acute Leukemia
Primary: Median Time in Days to Onset of Grade II-IV aGVHD by Day 100 After Study Treatment — 34 days
Head and Neck Squamous Cell Carcinoma
Primary: Major Pathologic Response — 22 Participants
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) or Radiographic Progression — 10 participants
Prostate Adenocarcinoma · Stage IIB Prostate Cancer AJCC v8 · Stage III Prostate Cancer AJCC v8
Primary: Freedom From Failure (FFF) — 7; 16; 5 Participants
Fragile X Syndrome
Primary: Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician — 3.7; 3.8 score on a scale
Tourette's Syndrome
Primary: Yale Global Tic Severity Scale - Total Tic Score — -5.6; -3.4 Score on a scale — p=<0.05
Lymphoma
Primary: Event-free Survival — 76 percentage of patient
Knee Osteoarthritis
Primary: Visual Analog Scale (VAS) — 5; 5; 5 points (1-10; higher = worse pain) — p=0.0001
Subcutaneous Fat
Primary: Assess Maximum Analyte Concentration of CBL-514 in Plasma (Cmax) — 137.6; 79.5 ng/mL
Depressive Disorder, Major
Primary: Change From Baseline in MADRS Total Score at Week 6 — -10.3; -13.6; -10.6; -10.0 Units on a scale — p=0.5414
Irritable Bowel Syndrome
Primary: Change in Abdominal Pain Scores — -12; -22.6 score on a scale — p=0.41
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 32.1; 79.5; 94.4 Percentage of participants
Alcohol Use Disorder
Primary: Percentage of Participants With Treatment Emergent Adverse Events — 11 Participants
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Complete Remission Rate After Chemotherapy — 38 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression-Free Survival Rate at 6 Months From Start of Study Treatment (Maintenance Pembrolizumab) — 5.0 Percentage of participants